| Ghrelin, n = 10 | Placebo, n = 10 |
---|---|---|
Age (years) | 70.8 (6.4) | 73.1 (5.6) |
Sex (males/females) | 10/0 | 9/1 |
BMI (kg/m2) | 18.4 (2.4) | 18.1 (2.3) |
Cigarettes (pack-years) | 59.1 (29.2) | 64.8 (25.1) |
Pulmonary function | Â | Â |
FEV1 (L) | 0.83 (0.21) | 0.82 (0.23) |
%FEV1 (% predicted) | 32.0 (9.4) | 33.3 (10.5) |
FEV1/FVC (%) | 41.7 (7.6) | 42.4 (8.0) |
VC (L) | 2.54 (0.42) | 2.62 (0.50) |
%VC (%) | 79.6 (11.0) | 86.1 (15.3) |
IC (L) | 1.63 (0.22) | 1.74 (0.38) |
DLco (% predicted) | 61.3 (23.8) | 72.4 (27.4) |
Exercise capacity in ICPET | Â | Â |
Peak work rate (Watt) | 36.0 (13.5) | 34.0 (9.7) |
Peak | 13.3 (3.7) | 13.4 (3.2) |
Medications | Â | Â |
LAMA | 7 | 5 |
SAMA | 2 | 2 |
LABA | 6 | 5 |
ICS | 4 | 1 |
Methylxanthines | 5 | 6 |
Comorbidity | Â | Â |
Angina pectoris | 2 | 0 |
PVC | 0 | 1 |